HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through its ambulatory ECG signal platform, announced it will host a conference call on August 13, 2026, at 4:30 p.m. ET. The call will cover the company's financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its innovative technology.
Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank will lead the call, which will include a question-and-answer session following prepared remarks. The company's platform is the first cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, enabling physicians to monitor cardiac health trends and detect acute conditions outside medical facilities.
HeartBeam's technology received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology. According to the press release, the company's platform is designed for portable devices that can be used wherever the patient is, delivering actionable heart intelligence.
The upcoming call is an opportunity for investors to understand how HeartBeam plans to commercialize its FDA-cleared technology and drive adoption. The company's strategy focuses on redefining cardiac health management by enabling care outside traditional clinical settings, potentially reducing costs and improving patient outcomes. For more details, the full press release is available at https://ibn.fm/sqGLs.
HeartBeam's technology addresses a significant need in cardiac care, where timely detection of arrhythmias and other conditions can be life-saving. By providing a portable, cable-free ECG solution, the company aims to empower patients and physicians with continuous monitoring capabilities. The FDA clearances mark critical milestones, and the company's next steps involve scaling production, building partnerships, and expanding market reach.
Investors and stakeholders can access the conference call by dialing in or listening to a webcast, details of which are expected to be released prior to the call. The company's recent news and updates are available in its newsroom at https://ibn.fm/BEAT. For cleared indications for use, refer to https://www.heartbeam.com/indications.
This announcement underscores HeartBeam's commitment to advancing cardiac care through innovation and strategic execution. As the company prepares to report its second-quarter results, the focus remains on delivering value to patients and shareholders alike.
